Drug Discovery · Boston, MA · Founded 2018 · Privately Held (backing)
Operator of a clinical-stage company designed to develop novel therapies for patients with life-altering cardiometabolic disorders. Imbria Pharmaceuticals is based in Boston, MA and was founded in 2018. It was valued at $132 million at its later-stage round in Dec 2025, the last priced event on record. It has raised $152 million across 2 recorded rounds; the latest was a $66.7 million Series B in Dec 2025.
PMV mark · valuation
$131.7M
Oct 2026
Priced at
its later-stage round
Dec 2025
Total raised
$151.9M
Last round
Later Stage VC (Series B)
Dec 2025
Team — not yet on record
No current team members for Imbria Pharmaceuticals are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Imbria Pharmaceuticals with a free account
·Watch Imbria Pharmaceuticals: the Monday email on marks, rounds and moves
